Phase III study of selpercatinib vs chemotherapy plus /- pembrolizumab in untreated RET positive non-small-cell lung cancer

被引：34

作者：

Solomon, Benjamin J. ^{[1
]}

Zhou, Cai Cun ^{[2
]}

Drilon, Alexander ^{[3
]}

Park, Keunchil ^{[4
]}

Wolf, Jurgen ^{[5
]}

Elamin, Yasir ^{[6
]}

Davis, Hannah M. ^{[7
]}

Soldatenkova, Victoria ^{[7
]}

Sashegyi, Andreas ^{[7
]}

Lin, Aimee Bence ^{[7
]}

Lin, Boris K. ^{[7
]}

Loong, Herbert H. ^{[8
]}

Novello, Silvia ^{[9
]}

Arriola, Edurne ^{[10
]}

Perol, Maurice ^{[11
]}

Goto, Koichi ^{[12
]}

Santini, Fernando C. ^{[13
]}

机构：

[1] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[2] Shanghai Pulm Hosp, Shanghai, Peoples R China

[3] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA

[4] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea

[5] Univ Hosp Cologne, Ctr Integrated Oncol, Cologne, Germany

[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[7] Eli Lilly & Co, Indianapolis, IN 46225 USA

[8] Chinese Univ Hong Kong, Hong Kong, Peoples R China

[9] Univ Turin, Dept Oncol, AOU San Luigi Orbassano, Turin, Italy

[10] Hosp del Mar, Barcelona, Spain

[11] Leon Berard Canc Ctr Lyon, Lyon, France

[12] Natl Canc Ctr Hosp East, Chiba, Japan

[13] Hosp Sirio Libanes, Ctr Oncol, Sao Paulo, Brazil

来源：

FUTURE ONCOLOGY | 2021年 / 17卷 / 07期

关键词：

non-small-cell lung cancer; Phase III trial; RET fusion-positive; RET kinase inhibitor; RET rearrangement; selpercatinib; targeted therapy; ALK; REARRANGEMENTS; EFFICACY; FUSIONS; IPILIMUMAB; MUTATIONS; BLOCKADE; NSCLC; EGFR; BRAF;

D O I：

10.2217/fon-2020-0935

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Selpercatinib, a novel, highly selective and potent, inhibitor of RET, demonstrated clinically meaningful antitumor activity with manageable toxicity in heavily pretreated and treatment-naive RET fusion-positive non-small-cell lung cancer patients in a Phase I/II clinical trial. LIBRETTO-431 (NCT04194944) is a randomized, global, multicenter, open-label, Phase III trial, evaluating selpercatinib versus carboplatin or cisplatin and pemetrexed chemotherapy with or without pembrolizumab in treatment-naive patients with locally advanced/metastatic RET fusion-positive nonsquamous non-small-cell lung cancer. The primary end point is progression-free survival by independent review. Key secondary end points include overall survival, response rate, duration of response and progression-free survival.

引用

页码：763 / 773

页数：11

共 50 条

[1] Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer
Drilon, A.
Oxnard, G. R.
Tan, D. S. W.
Loong, H. H. F.
Johnson, M.
Gainor, J.
McCoach, C. E.
Gautschi, O.
Besse, B.
Cho, B. C.
Peled, N.
Weiss, J.
Kim, Y. -J.
Ohe, Y.
Nishio, M.
Park, K.
Patel, J.
Seto, T.
Sakamoto, T.
Rosen, E.
Shah, M. H.
Barlesi, F.
Cassier, P. A.
Bazhenova, L.
De Braud, F.
Garralda, E.
Velcheti, V.
Satouchi, M.
Ohashi, K.
Pennell, N. A.
Reckamp, K. L.
Dy, G. K.
Wolf, J.
Solomon, B.
Falchook, G.
Ebata, K.
Nguyen, M.
Nair, B.
Zhu, E. Y.
Yang, L.
Huang, X.
Olek, E.
Rothenberg, S. M.
Goto, K.
Subbiah, V.
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (09): : 813 - 824
[2] Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
Paz-Ares, L.
Luft, A.
Vicente, D.
Tafreshi, A.
Gumus, M.
Mazieres, J.
Hermes, B.
Senler, F. Cay
Csoszi, T.
Fulop, A.
Rodriguez-Cid, J.
Wilson, J.
Sugawara, S.
Kato, T.
Lee, K. H.
Cheng, Y.
Novello, S.
Halmos, B.
Li, X.
Lubiniecki, G. M.
Piperdi, B.
Kowalski, D. M.
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (21): : 2040 - 2051
[3] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
Gandhi, L.
Rodriguez-Abreu, D.
Gadgeel, S.
Esteban, E.
Felip, E.
De Angelis, F.
Domine, M.
Clingan, P.
Hochmair, M. J.
Powell, S. F.
Cheng, S. Y. -S.
Bischoff, H. G.
Peled, N.
Grossi, F.
Jennens, R. R.
Reck, M.
Hui, R.
Garon, E. B.
Boyer, M.
Rubio-Viqueira, B.
Novello, S.
Kurata, T.
Gray, J. E.
Vida, J.
Wei, Z.
Yang, J.
Raftopoulos, H.
Pietanza, M. C.
Garassino, M. C.
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22): : 2078 - 2092
[4] Durability of Efficacy with Selpercatinib in Patients (pts) with RET Fusion plus Non-Small-Cell Lung Cancer (NSCLC)
Drillon, Alexander E.
Subbiah, Vivek
Gautschi, Oliver
Tomasini, Pascale
De Braud, Filippo G.
Solomon, Benjamin
Tan, Daniel Shao-Weng
Alonso, Guzman
Wolf, Juergen
Park, Keunchil
Goto, Koichi
Soldatenkova, Victoria
Szymczak, Sylwia
Barker, Scott S.
Puri, Tarun
Lin, Aimee K.
Loong, Herbert
Besse, Benjamin
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 150 - 150
[5] Selpercatinib (LOXO-292) in patients with RET-fusion plus non-small-cell lung cancer
Goto, K.
Oxnard, G.
Tan, D. S. -W.
Loong, H. H. F.
Bauer, T.
Gainor, J.
McCoach, C.
Gautschi, O.
Besse, B.
Cho, B. C.
Peled, N.
Weiss, J.
Kim, Y. J.
Ohe, Y.
Horiike, A.
Park, K.
Huang, X.
Olek, E.
Subbiah, V.
Drilon, A.
SWISS MEDICAL WEEKLY, 2020, : 7S - 7S
[6] Selpercatinib (LOXO-292) in patients with RET-fusion plus Non-Small-Cell Lung Cancer
Gautschi, O.
Goto, K.
Oxnard, G.
Tan, D. S. -W.
Loong, H. H. F.
Bauer, T.
Gainor, J.
McCoach, C.
Besse, B.
Cho, B. C.
Peled, N.
Weiss, J.
Kim, Y. J.
Ohe, Y.
Horiike, A.
Park, K.
Huang, X.
Olek, E.
Subbiah, V.
Drilon, A.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 149 - 150
[7] Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer patients: a systematic review
Yunita, E.
Santoso, V. Febrian
Santoso, A. Febrian
Kurniawan, A.
ANNALS OF ONCOLOGY, 2024, 35 : S1377 - S1378
[8] LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer
Tsuboi, Masahiro
Goldman, Jonathan W.
Wu, Yi-Long
Johnson, Melissa L.
Paz-Ares, Luis
Yang, James Chih-Hsin
Besse, Benjamin
Su, Weiji
Chao, Bo H.
Drilon, Alexander
FUTURE ONCOLOGY, 2022, 18 (28) : 3133 - 3141
[9] Comparison of Chemotherapy Plus Pembrolizumab vs. Chemotherapy Alone in EGFR-Mutant Non-small-Cell Lung Cancer Patients
Chen, Minjiang
Xu, Yan
Zhao, Jing
Liu, Xiaoyan
Liu, Xiangning
Zhang, Dongming
Shi, Yuequan
Zhang, Li
Zhong, Wei
Wang, Mengzhao
CLINICAL LUNG CANCER, 2023, 24 (03) : 278 - 286
[10] Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non-small-cell lung cancer: A multicenter retrospective trial
Matsumoto, Hiromi
Kobayashi, Nobuaki
Somekawa, Kohei
Fukuda, Nobuhiko
Kaneko, Ayami
Kamimaki, Chisato
Kubo, Sousuke
Tanaka, Katsushi
Tagami, Yoichi
Teranishi, Shuhei
Watanabe, Keisuke
Horita, Nobuyuki
Hara, Yu
Yamamoto, Masaki
Kudo, Makoto
Koizumi, Harumi
Miura, Kenji
Miyazawa, Naoki
Kaneko, Takeshi
THORACIC CANCER, 2022, 13 (02) : 228 - 235

← 1 2 3 4 5 →